TICKERNERD
Menu
ARTLARTLHealthcare · Biotechnology

ARTL Stock Forecast: Artelo Biosciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.69
−2.85% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap
$3.2M
Ticker Nerd rank
17 / 100
Median analyst target
—
Analysts covering
1
Total return, dividends reinvested
1W
−12.4%
1M
−38.2%
YTD
−81.1%
1Y
−97.6%
From 52W high
−97.6%
From 52W low
0.0%
$1
$29
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARTL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Artelo Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
17 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Volatility
62
Issuance
52
Growth
42
Momentum
27
Revisions
25
Accruals
18
Quality
12
Value
4

Size (98): Smaller than most of the companies we track.

Value (4): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARTL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARTL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30Oct 25Jan 26Apr 26Jul 26ARTL

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Nov 2025Maxim GroupDowngradeHold—
8 Sept 2025D. Boral CapitalDowngradeHold—
26 Aug 2025D. Boral CapitalMaintainsBuy—
18 Aug 2025D. Boral CapitalMaintainsBuy—
6 Aug 2025D. Boral CapitalMaintainsBuy—
4 Aug 2025D. Boral CapitalMaintainsBuy—
8 July 2025D. Boral CapitalUpgradeBuy—
11 June 2025D. Boral CapitalDowngradeHold—
6 June 2025D. Boral CapitalMaintainsBuy—
28 Apr 2025D. Boral CapitalMaintainsBuy—
2 Apr 2025D. Boral CapitalMaintainsBuy—
4 Mar 2025HC Wainwright & Co.ReiteratesBuy—
3 Mar 2025D. Boral CapitalMaintainsBuy—
27 Feb 2025D. Boral CapitalMaintainsBuy—
14 Jan 2025D. Boral CapitalMaintainsBuy—
9 Dec 2024D. Boral CapitalMaintainsBuy—
9 Dec 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy$5.00
1 Oct 2024EF HuttonInitiatesBuy$6.00
14 Aug 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARTL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ARTL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Artelo Biosciences, Inc. (ARTL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 76% of US stocks

Price / sales
—
Price / book
0.6×

Cheaper than 84% of US stocks

EV / EBITDA
0.1×

Cheaper than 60% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−705.7%

Higher than 2% of US stocks

Return on assets
−127.9%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ARTL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARTLArtelo Biosciences, Inc.$3.2M
17
GNPXGenprex, Inc.$3.2M
9
CRISCuris, Inc.$3.3M
37
MTNBMatinas BioPharma Holdings, Inc.$2.9M
46
CLDICalidi Biotherapeutics, Inc.$3.5M
23
GRIGRI Bio, Inc.$3.6M
30
VBIOValion Bio, Inc.$2.7M
2

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Artelo Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARTL news & analysis

Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13

GlobeNewsWire · 20 Aug 2026positive

Artelo Biosciences announced that the Japanese Patent Office issued a notification of allowance with a Decision to Grant for its patent application covering the intended commercial formulation of ART27.13, the company's peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials.

Why it matters — The granted Japanese patent helps protect the commercial formulation of ART27.13, a key pipeline asset, within an important territory.

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

GlobeNewsWire · 17 Aug 2026positive

Artelo Biosciences announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering the intended commercial formulation of ART27.13, its peripherally selective cannabinoid agonist currently being evaluated in two Phase 2 studies—the CAReS trial for cancer-related anorexia and the DREAM study for glaucoma or ocular hypertension. The patent is expected to extend protection for ART27.13 through 2041.

Why it matters — Securing this patent allowance for the commercial formulation of its lead investigational drug could help protect ART27.13 well into 2041, an important milestone for Artelo's pipeline given the drug is already in two Phase 2 trials.

Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results

GlobeNewsWire · 13 Aug 2026neutral

Artelo Biosciences, a clinical-stage pharmaceutical company, provided a business update and announced its financial and operational results for the second quarter ended June 30, 2026. The announcement was made on August 13, 2026.

Why it matters — ARTL watchers would care because the report provides the latest operational and financial status of the company's clinical-stage programs.

FAQ

Frequently asked questions about ARTL stock

Is ARTL stock a buy right now?

Of the 1 analysts covering Artelo Biosciences, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Artelo Biosciences, Inc. 17 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARTL?

As at 22 Aug 2026, Artelo Biosciences, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the ARTL stock forecast for 2030?

No analyst covering Artelo Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARTL are extrapolating price history, which says nothing about the business.

How has ARTL stock performed over the past year?

Artelo Biosciences, Inc. returned -97.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Artelo Biosciences, Inc. do?

Artelo Biosciences Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system.

What is the latest news on ARTL?

The most recent item we track (GlobeNewsWire, 20 Aug 2026): "Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13". Artelo Biosciences announced that the Japanese Patent Office issued a notification of allowance with a Decision to Grant for its patent application covering the intended commercial formulation of ART27.13, the company's peripherally selective dual cannabinoid agonist currently being evaluated in two Phase 2 clinical trials.

Company

About Artelo Biosciences, Inc.

Artelo Biosciences Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline features ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist in Phase 1b/2a clinical trials for treating cancer-related anorexia and weight loss. ART12.11, a proprietary cannabidiol cocrystal with tetramethylpyrazine, targets anxiety, depression, post-traumatic stress disorder, epilepsy, insomnia, pain, and inflammation. ART26.12, a fatty acid binding protein 5 inhibitor, addresses chemotherapy-induced peripheral neuropathy, diabetic neuropathy, osteoarthritis pain, prostate and breast cancer, dermatologic conditions, and anxiety disorders. These candidates aim to fulfill unmet medical needs in oncology supportive care, neurology, psychiatry, and pain management. Founded in 2011 and headquartered in Solana Beach, California, Artelo Biosciences Inc. applies advanced scientific and regulatory expertise to advance its portfolio of innovative, proprietary therapies.

CEO Mr. Gregory D. Gorgas M.B.A. · 7 employees · United States · https://artelobio.com